Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure - Results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)

被引:192
作者
Mark, Daniel B.
Nelson, Charlotte L.
Anstrom, Kevin J.
Al-Khatib, Sana M.
Tsiatis, Anastasios A.
Cowper, Patricia A.
Clapp-Channing, Nancy E.
Davidson-Ray, Linda
Poole, Jeanne E.
Johnson, George
Anderson, Jill
Lee, Kerry L.
Bardy, Gust H.
机构
[1] Duke Clin Res Inst, Outcomes Res Grp, Durham, NC 27715 USA
[2] Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA
[3] N Carolina State Univ, Dept Stat, Raleigh, NC 27695 USA
[4] Seattle Inst Cardiac Res, Seattle, WA USA
[5] Univ Washington, Med Ctr, Seattle, WA 98195 USA
关键词
amiodarone; defibrillators; implantable; heart failure; congestive; quality-adjusted life years; cost-benefit analysis;
D O I
10.1161/CIRCULATIONAHA.105.581884
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background - In the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), implantable cardioverter-defibrillator (ICD) therapy significantly reduced all-cause mortality rates compared with medical therapy alone in patients with stable, moderately symptomatic heart failure, whereas amiodarone had no benefit on mortality rates. We examined long-term economic implications of these results. Methods and Results - Medical costs were estimated by using hospital billing data and the Medicare Fee Schedule. Our base case cost-effectiveness analysis used empirical clinical and cost data to estimate the lifetime incremental cost of saving an extra life-year with ICD therapy relative to medical therapy alone. At 5 years, the amiodarone arm had a survival rate equivalent to that of the placebo arm and higher costs than the placebo arm. For ICD relative to medical therapy alone, the base case lifetime cost-effectiveness and cost-utility ratios (discounted at 3%) were $38 389 per life-year saved (LYS) and $41 530 per quality-adjusted LYS, respectively. A cost-effectiveness ratio <$100 000 was obtained in 99% of 1000 bootstrap repetitions. The cost-effectiveness ratio was sensitive to the amount of extrapolation beyond the empirical 5-year trial data: $127 503 per LYS at 5 years, $88 657 per LYS at 8 years, and $58 510 per LYS at 12 years. Because of a significant interaction between ICD treatment and New York Heart Association class, the cost-effectiveness ratio was $29 872 per LYS for class II, whereas there was incremental cost but no incremental benefit in class III. Conclusions - Prophylactic use of single-lead, shock-only ICD therapy is economically attractive in patients with stable, moderately symptomatic heart failure with an ejection fraction <= 35%, particularly those in NYHA class II, as long as the benefits of ICD therapy observed in the SCD- HeFT persist for at least 8 years.
引用
收藏
页码:135 / 142
页数:8
相关论文
共 15 条
  • [1] Clinical and economic implications of the multicenter automatic defibrillator implantation trial-II
    Al-Khatib, SM
    Anstrom, KJ
    Eisenstein, EL
    Peterson, ED
    Jollis, JG
    Mark, DB
    Li, Y
    O'Connor, CM
    Shaw, LK
    Califf, RM
    [J]. ANNALS OF INTERNAL MEDICINE, 2005, 142 (08) : 593 - 600
  • [2] Estimating medical costs with censored data
    Bang, H
    Tsiatis, AA
    [J]. BIOMETRIKA, 2000, 87 (02) : 329 - 343
  • [3] Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure
    Bardy, GH
    Lee, KL
    Mark, DB
    Poole, JE
    Packer, DL
    Boineau, R
    Domanski, M
    Troutman, C
    Anderson, J
    Johnson, G
    McNulty, SE
    Clapp-Channing, N
    Davidson-Ray, LD
    Fraulo, ES
    Fishbein, DP
    Luceri, RM
    Ip, JH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (03) : 225 - 237
  • [4] The growing mismatch between patient longevity and the service life of Implantable cardioverter-defibrillators
    Hauser, RG
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (12) : 2022 - 2025
  • [5] Evidence-based medicine and policy: The case of the implantable cardioverter defibrillator
    Hlatky, MA
    Sanders, GD
    Owens, DK
    [J]. HEALTH AFFAIRS, 2005, 24 (01) : 42 - 51
  • [6] Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias - Results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy
    Larsen, G
    Hallstrom, A
    McAnulty, J
    Pinski, S
    Olarte, A
    Sullivan, S
    Brodsky, M
    Powell, J
    Marchant, C
    Jennings, C
    Akiyama, T
    [J]. CIRCULATION, 2002, 105 (17) : 2049 - 2057
  • [7] Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes
    Mark, DB
    Harrington, RA
    Lincoff, AM
    Califf, RM
    Nelson, CL
    Tsiatis, AA
    Buell, H
    Mahaffey, KW
    Davidson-Ray, L
    Topol, EJ
    [J]. CIRCULATION, 2000, 101 (04) : 366 - 371
  • [8] Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients - Results from the ESSENCE randomized trial
    Mark, DB
    Cowper, PA
    Berkowitz, SD
    Davidson-Ray, L
    DeLong, ER
    Turpie, AGG
    Califf, RM
    Weatherley, B
    Cohen, M
    [J]. CIRCULATION, 1998, 97 (17) : 1702 - 1707
  • [9] COST-EFFECTIVENESS OF THROMBOLYTIC THERAPY WITH TISSUE-PLASMINOGEN ACTIVATOR AS COMPARED WITH STREPTOKINASE FOR ACUTE MYOCARDIAL-INFARCTION
    MARK, DB
    HLATKY, MA
    CALIFF, RM
    NAYLOR, CD
    LEE, KL
    ARMSTRONG, PW
    BARBASH, G
    WHITE, H
    SIMOONS, ML
    NELSON, CL
    CLAPPCHANNING, N
    KNIGHT, JD
    HARRELL, FE
    SIMES, J
    TOPOL, EJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (21) : 1418 - 1424
  • [10] Medical economics and the assessment of value in cardiovascular medicine: Part I
    Mark, DB
    Hlatky, MA
    [J]. CIRCULATION, 2002, 106 (04) : 516 - 520